Atopic Dermatitis Complete Guide — Treatment, Comorbidity, 6 Myths

1. Epidemiology and natural history

Atopic dermatitis (AD) is the most common chronic inflammatory skin disease in children. Global pediatric prevalence is 15–30% (2–10% in adults); Taiwan pediatric prevalence is ~8–10% (Saunes 2024 systematic review; Taiwan NHI data). Onset peaks before age 1 in 60% and before age 5 in 85%; a second peak in adolescence/adulthood accounts for ~25% of adult AD cases.

The atopic march describes the sequential development of food allergy → asthma → allergic rhinitis after AD, particularly in severe infantile AD; Hill (JAMA Pediatr 2014) and Paller (JACI 2019) frame this as the rationale for early barrier repair and early oral food tolerance strategies.

Natural history: infantile AD (0–2 yr) clears before age 5 in ~60%; childhood AD (2–12 yr) improves notably before puberty in 40–60%; 30–50% persist into adulthood. Adult-onset AD (about a quarter of adult AD) is typically more chronic and treatment-resistant.

2. Pathophysiology — the triad

AD pathophysiology is a self-amplifying triangle of barrier dysfunction, Th2-skewed immunity, and microbiome dysbiosis. Modern targeted agents almost all sit on the second leg, blocking specific Th2 cytokine axes.

① Barrier dysfunction

• Filaggrin (FLG) mutations: 20–50% of European/American AD have FLG loss-of-function variants; Asian populations carry distinct variants beyond R501X / 3321delA
• Lipid imbalance: decreased ceramides (especially ceramide-3, ceramide-NS); abnormal cholesterol : fatty acid : ceramide ratio (ideal 1:1:3)
• Increased TEWL: elevated transepidermal water loss → easier penetration of allergens and microbes → portal for sensitization

② Th2-skewed immunity — mapped to drug targets

Acute lesions are Th2/Th22-driven; IL-4 and IL-13 impair barrier repair and drive IgE class-switching; IL-31 is the dominant pruritus cytokine; TSLP is the keratinocyte-derived upstream alarmin. Chronic, lichenified lesions (especially in Asian populations) recruit Th1/Th17. The table below maps each biologic to its cytokine axis:

③ Skin microbiome dysbiosis

• S. aureus dominance: 90%+ of lesions colonized; staphylococcal enterotoxin acts as a superantigen, directly activating large T-cell pools and triggering flares
• Reduced diversity + biofilm: commensals (S. epidermidis, Cutibacterium) decline; lesional biofilm shields S. aureus from antibiotic clearance

How to distinguish from contact dermatitis?

For the distinction (allergic vs irritant), Patch Test indications, allergen avoidance, and treatment ladder, see the complete contact dermatitis guide.

3. Diagnosis — two criteria sets and five differentials

AD is a purely clinical diagnosis; serum IgE, TARC, and allergen panels are not diagnostic and not recommended for routine use (Werfel 2024 S3).

Hanifin & Rajka 1980 — 4 majors + 23 minors

Diagnosis requires ≥ 3 of 4 major plus ≥ 3 of 23 minor features.

• Major (all 4)： ① pruritus； ② typical morphology and distribution (infants: face/extensor; children/adolescents: flexural; adults: hand and flexural lichenification)； ③ chronic relapsing course (> 6 mo)； ④ personal or family history of atopy (asthma, allergic rhinitis, AD)
• Common 8 minor (of 23)： ① xerosis； ② keratosis pilaris； ③ elevated serum IgE； ④ early onset (< 2 yr)； ⑤ Dennie-Morgan infraorbital fold； ⑥ periorbital darkening； ⑦ white dermographism； ⑧ hand/foot eczema

UK Working Party 1994 (Williams) — clinic-friendly

Required: itchy skin in the past 12 months, PLUS ≥ 3 of： ① flexural involvement (antecubital, popliteal, anterior ankle/neck; cheeks in < 4 yr)； ② personal atopy (or first-degree relative if < 4 yr)； ③ generalized dry skin in the past year； ④ visible flexural eczema (or cheeks/forehead in < 4 yr)； ⑤ onset before age 2 (only applicable in those ≥ 4 yr). Williams 1994 BJD, PMID 7918015.

Differential — 5 quick rule-outs

4. Severity assessment

On-site calculators: EASI · SCORAD · DLQI · POEM

5. Comorbidity systems screening — every visit

AD is no longer viewed as "skin only." Population studies (Drucker JID 2017; Schonmann BJD 2020) confirm AD as a systemic inflammatory disease linked to mental health, cardiovascular, bone, and infection risk — treatment choices (especially biologic vs JAK) must factor these in.

① Atopic march

• Food allergy OR ~2.7 (highest in severe infantile AD); early peanut introduction (LEAP) reduces risk by 80%
• Asthma OR ~3.0; 30–50% in severe pediatric AD (10–15% in mild)
• Allergic rhinitis OR ~2.4; 50–75% comorbidity in severe AD
• EoE: 2–3× general population risk; investigate when dysphagia or food impaction occurs

(Sources: Hill DA et al. JAMA Pediatr 2014; Paller AS et al. JACI 2019)

② Mental health

• Depression OR ~1.7 (14–20% in adult severe AD vs 8% general population)
• Anxiety OR ~1.8 (17–25% vs 12%)
• Suicidal ideation OR ~1.4 in severe AD (Schonmann BJD 2020)
• PHQ-2 two-item screen： ① Over the past 2 weeks, little interest or pleasure in doing things？ ② Over the past 2 weeks, feeling down, depressed, or hopeless? Either positive → escalate to PHQ-9 / referral

③ Cardiovascular (adult severe)

Severe AD: MI HR ~1.4, stroke HR ~1.2 (Silverberg JID 2015; Andersen BJD 2018 nationwide). Mechanism: systemic IL-13/IL-4-driven endothelial inflammation overlapping the IL-1β/IL-6 atherosclerosis axis. Clinical: routine BP, lipids, glucose in adult severe AD; ASCVD assessment before any JAK inhibitor (see treatment section).

④ Bone health

Long-term high-potency topical steroids (daily, body-wide, ≥ 12 mo) or cumulative oral prednisolone ≥ 5 mg/day × 3 mo lower BMD by ~3–5%. DEXA indicators: meet either threshold → baseline DEXA, repeat every 1–2 yr; supplement vitamin D + calcium, smoking/alcohol cessation, weight-bearing exercise.

⑤ Skin infection

• Emergency — eczema herpeticum (Kaposi varicelliform eruption): rapidly spreading clustered vesicles/pustules + fever + lymphadenopathy → urgent IV acyclovir; ophthalmology consult if periocular
• Common — MRSA / S. aureus impetigo: thick yellow crust, exudate; short-course cephalexin/dicloxacillin; in MRSA-endemic areas consider doxycycline or TMP-SMX
• Pediatric — molluscum: usually self-resolves; scratching worsens AD; cantharidin or cryotherapy for extensive/persistent cases

⑥ 5-minute follow-up checklist

• □ Food allergy (mandatory in < 5 yr)
• □ Asthma / allergic rhinitis symptoms (cough, nocturnal wheeze, congestion)
• □ Sleep (POEM Q6 or report of nocturnal itch)
• □ PHQ-2 two items; positive → PHQ-9 / referral
• □ Suicidal ideation (mandatory in severe / adolescent)
• □ Infection signs (sudden worsening, vesicles, honey crust, fever)
• □ Cumulative steroid exposure (oral / potent topical) → DEXA indication

Topical treatment ladder

Moisturizer dosing, bathing, TCS class 1-7, TCI, crisaborole, topical ruxolitinib, wet wrap — see the complete AD topical treatment guide.

6. Treatment ladder

STEP 0 — Foundation (everyone, daily)

• Moisturizer: ceramide / glycerin / petrolatum-based; apply within 3 min of bathing (soak-and-seal); 200–400 g/week for adults (Sidbury 2023 strong rec)
• Trigger management: sweat (rinse after exercise), clothing (cotton, avoid wool), avoid overheating; allergen avoidance only during acute flare, not blanket
• Bleach bath: Sidbury 2023 conditional rec — ¼ cup of 2.5% NaOCl in half a tub of warm water (~0.005%), soak 5–10 min, 1–2×/week; for patients with recurrent S. aureus infection — no benefit shown in unselected populations

STEP 1 — Acute topical

Topical corticosteroids (TCS) — US 7-class system: Class 1 = ultra-potent (clobetasol 0.05%), Class 7 = lowest (hydrocortisone 1%). Site matching: face / infants / folds → Class 6–7; trunk and limbs → Class 3–5; thick palms/soles short-term → Class 1–2.

FTU dosing: 1 FTU (~0.5 g) covers ~2 adult palms. Proactive maintenance: post-flare, twice-weekly TCS or TCI on relapse-prone sites — relapse reduction 30–60% (Wollenberg 2008; Sidbury 2023 strong rec, evidence level A).

Steroid-sparing topicals — five options: all non-steroidal; differ mainly in age range, site, and mechanism.

STEP 2 — Moderate: phototherapy

NB-UVB (narrowband UVB, 311 nm): 2–3×/week × 8–12 weeks; average 24 sessions to reach EASI-75. Safe in children, pregnancy, and lactation; main barrier is time and transportation. The bridge of choice when topicals fail but biologic thresholds aren't yet met.

STEP 3 — Moderate-severe: biologics + JAK + conventional

Biologics (4 agents)

Oral JAK inhibitors (3 agents)

ORAL Surveillance (Ytterberg NEJM 2022): in RA patients ≥ 50 yr with ≥ 1 CV risk factor, JAKs raised MACE / cancer / VTE vs TNF inhibitors — FDA applied this as a class label. Pre-Tx workup: CBC with differential, LFT/RFT, lipid panel, HBV/HCV, HIV, TB (IGRA + CXR), zoster vaccine if ≥ 50 yr.

Conventional immunomodulators (NHI bridge / out-of-pocket): cyclosporine 3–5 mg/kg/d short-term (≤ 1 yr) is the bridge of choice; methotrexate 7.5–15 mg/week; azathioprine 100–150 mg/d (TPMT not routinely tested in Taiwan). Largely supplanted by dupilumab but remain useful when biologics aren't reimbursable.

STEP 4 — Taiwan NHI status (2026)

• NHI (revised 2025/6/1) covers dupilumab, upadacitinib, and abrocitinib for moderate-severe AD in ≥ 12 yr: EASI ≥ 16, inflamed BSA ≥ 30%, IGA 3–4, disease ≥ 6 months + complete prior course (phototherapy ≥ 2×/wk for 12 weeks AND at least 2 of 3 MTX/AZA/CsA at adequate dose ≥ 12 weeks)
• dupilumab coverage for 6–12 year-olds (less stringent — failure of one systemic immunosuppressant suffices)
• Week-16 review requires EASI 50 to continue. Pause continuation: biologics after 1 year if EASI ≤ 16; JAK inhibitors after 2 years if EASI ≤ 16 (per 2025/6/1 revision)
• Upa and Abro can only be used one at a time — switching only allowed for intolerable AE; Upa 30 mg restricted to ≥ 18 yr with EASI ≥ 20
• Tralokinumab, lebrikizumab, nemolizumab, baricitinib (for AD): not NHI-reimbursed; fully out-of-pocket (~NT$ 30,000–50,000 per month)

Reimbursement conditions change frequently; refer to official NHI announcements.

Pediatric atopic dermatitis

For pediatric AD moisturizer routines, bathing, food introduction, topical TCI, and avoiding steroid phobia, see the complete pediatric AD guide.

AD in special populations (infants, pregnancy, elderly, refractory)

For pediatric dose adjustments, pregnancy/lactation safety, elderly JAK contraindications, and refractory AD switching, see AD in special populations.

7. Special populations — quick reference

• Infants / children: see Pediatric AD. Key points: face only Class 6–7, TCI from ≥ 3 months, dupilumab approved from ≥ 6 months
• Pregnancy / lactation: dupilumab is safe (Category B; multiple case series and registry data); JAKs contraindicated (teratogenic); NB-UVB safe; potent TCS short-term acceptable (low systemic absorption); short-term oral GC as bridge OK
• Older adults (≥ 65 yr): caution with JAKs (ORAL Surveillance); dupilumab has the best safety profile; for phototherapy watch for cumulative NMSC risk and visual issues

8. Six common myths

See "STEP 1" for class-by-site matching. Face, folds, and infants take Class 6–7 only; trunk and limbs in flare use Class 3–5 for ≤ 4 weeks then transition to proactive. Atrophy, purpura, and telangiectasia almost exclusively follow wrong-potency + wrong-site + daily continuous use ≥ 12 months.

Hajar 2015 JAAD systematic review defines TSW as long-term (≥ 1 yr) daily mid-high-potency use on face/genitals, with redness/burning/oozing extending beyond original lesions 1–2 weeks after self-discontinuation. Short-term use plus proactive maintenance does not cause TSW; suspected cases should be evaluated by dermatology, not self-tapered.

See Section 1 (natural history). The cost of "wait it out" is repeated scratching → barrier disruption → allergen sensitization → increased food allergy / asthma / rhinitis risk (Hill JAMA Pediatr 2014). Early aggressive moisturization + inflammation control is the strongest evidence-based prevention strategy for the atopic march.

Itch → scratch → barrier disruption → allergen + S. aureus penetration → IL-31 / IL-4 / IL-13 release → more itch → lichenification. Breaking the cycle: nighttime antihistamine, short nails, cold compress, generous moisturization, full-strength TCS in flare, and escalation to dupilumab / nemolizumab when needed. In the ARCADIA trial, nemolizumab achieved significant itch relief by week 1 — proof that targeting itch alone changes the disease.

Allergy testing detects sensitization, not clinical allergy. The root pathology is the barrier + Th2 + microbiome triangle (Section 2). Pediatric food allergy < 30% and most outgrow by age 5. Testing is meaningful only with： ① clearly time-locked immediate reaction (within 30 min – 2 hr)； ② recurrent eczema in the same anatomic site (patch test for contact)； ③ severe infantile AD with multiple food reactions on history.

Patients believing "no steroids" apply liberally long-term — and ironically receive higher-potency Class 1 steroid exposure than any prescriber would give, with predictable atrophy and withdrawal. Heavy metals absorb transcutaneously, causing renal and neurologic damage. Discuss any alternative remedy with your dermatologist; the genuinely non-steroidal options are all prescription (TCI, crisaborole, roflumilast, tapinarof, ruxolitinib).

9. Patient FAQ

Q1: How do I pick a moisturizer?

Pick any product containing ceramide, glycerin, or petrolatum; cost is irrelevant. La Roche-Posay Lipikar AP+M, Avène Xeracalm, Cetaphil RestoraDerm, Aveeno, Bioderma Atoderm are all reasonable choices. Volume matters more than brand: ≥ 1×/day, within 3 min of bathing, 200–400 g/week for adults.

Q2: How long until AD clears?

See Myth 3 and Section 1 (natural history). Infantile AD remits before age 5 in ~60%; childhood- and adult-onset typically persist, but biologics and JAKs now keep most moderate-severe adult AD nearly asymptomatic.

Q3: Do I really need to avoid certain foods?

90% of adult AD does not require dietary restriction. Children avoid foods only when an IgE-mediated allergy is confirmed (clear temporal relationship + positive antibody); blanket avoidance of dairy / eggs / seafood causes malnutrition and growth delay. A positive 100-panel test ≠ true allergy (see Myth 5).

Q4: How long can I keep using my steroid cream?

No fixed limit during acute flare — match potency to site (face/infant Class 6–7; trunk Class 3–5; palms/soles short-term Class 1–2). Daily potent TCS use > 3 months should transition to TCI / crisaborole / roflumilast / tapinarof / ruxolitinib or escalate to dupilumab. See STEP 1.

Q5: What does Taiwan NHI cover?

See STEP 4. In short: topical TCS / TCI / crisaborole are reimbursed; cyclosporine has conditional coverage; dupilumab and upadacitinib (since 2024-04) are conditionally reimbursed for moderate-severe adult AD; tralokinumab / lebrikizumab / nemolizumab are out-of-pocket or unavailable.

10. Bottom line — 4 things in AD care

1. Daily moisturization is the foundation (80% of treatment effect) — ceramide-based, applied within 3 minutes of bathing
2. Don't fear potency-matched steroids in flare — extinguish acute inflammation; chronic inflammation harms the skin far more than properly used short-term TCS
3. Don't tough it out in moderate-severe disease: dupilumab / JAKs have transformed prognosis — escalate when mid-potency TCS + TCI fails
4. Screen comorbidity: mental health (PHQ-2), CV (before JAK), infection (eczema herpeticum is an emergency), bone (cumulative steroid exposure) — these decisions feed directly into drug choice

Further reading:Related atopic dermatitis deep-dive articles: AD topical treatment — complete patient guide、AD comorbidities & special populations、Contact dermatitis (differential diagnosis)、Infant & pediatric AD — complete care。

Further reading:see "25 most-asked dermatology questions〉。

References

1. Diagnosis and classification
2. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl. 1980;92:44-47.
3. Williams HC, Burney PG, Hay RJ, et al. The U.K. Working Party's diagnostic criteria for atopic dermatitis. Br J Dermatol. 1994;131(3):383-396. PMID: 7918015.
4. Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis. Section 1. Diagnosis. J Am Acad Dermatol. 2014;70(2):338-351. PMID: 24290431.
5. Severity assessment
6. Hanifin JM, Thurston M, Omoto M, et al. The Eczema Area and Severity Index (EASI). Exp Dermatol. 2001;10(1):11-18.
7. Kunz B, Oranje AP, Labreze L, et al. Clinical validation and guidelines for the SCORAD index. Dermatology. 1997;195(1):10-19.
8. Charman CR, Venn AJ, Williams HC. The Patient-Oriented Eczema Measure. Arch Dermatol. 2004;140(12):1513-1519.
9. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI). Clin Exp Dermatol. 1994;19(3):210-216.
10. Guidelines and consensus
11. Sidbury R, Davis DMR, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2023;89(1):e1-e20.
12. Davis DMR, Drucker AM, Alikhan A, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. 2024;90(2):e43-e56.
13. Goulden V, Ling TC, Babakinejad P, et al. British Association of Dermatologists and British Photodermatology Group guidelines for narrowband ultraviolet B phototherapy 2022. Br J Dermatol. 2022;187(3):295-308. [Source]
14. Davis DMR, et al. AAD focused update on atopic dermatitis topical and systemic therapies. J Am Acad Dermatol. 2025;93(3):745.e1-e7.
15. Werfel T, Heratizadeh A, Aberer W, et al. S3 Guideline atopic dermatitis Part 1 — General aspects, topical and non-drug therapies. J Dtsch Dermatol Ges. 2024;22(1):137-153. PMID: 38171719.
16. Werfel T, et al. S3 Guideline atopic dermatitis Part 2 — Systemic treatment. J Dtsch Dermatol Ges. 2024;22(2):307-320. PMID: 38161245.
17. Wollenberg A, Barbarot S, Bieber T, et al. ETFAD/EADV Eczema task force 2020 position paper. J Eur Acad Dermatol Venereol. 2020;34(12):2717-2744. PMID: 33205485.
18. Taiwanese Dermatological Association. Consensus for the management of atopic dermatitis: 2020 update.
19. Comorbidity and systemic impact
20. Drucker AM, Wang AR, Li WQ, et al. The burden of atopic dermatitis. J Invest Dermatol. 2017;137(1):26-30.
21. Schonmann Y, Mansfield KE, Hayes JF, et al. Atopic eczema in adulthood and risk of depression and anxiety. Br J Dermatol. 2020;182(1):82-90.
22. Patel KR, Immaneni S, Singam V, et al. Association between atopic dermatitis, depression, and suicidal ideation. J Am Acad Dermatol. 2019;80(2):402-410.
23. Silverberg JI. Association between adult atopic dermatitis, cardiovascular disease, and increased heart attacks. J Invest Dermatol. 2015;135(3):721-728.
24. Andersen YMF, Egeberg A, Gislason GH, et al. Atopic dermatitis and risk of cardiovascular disease and all-cause mortality. Br J Dermatol. 2018;178(2):e41-e42.
25. Hill DA, Spergel JM. The atopic march: critical evidence and clinical relevance. Ann Allergy Asthma Immunol. 2018;120(2):131-137 (review of Hill 2014 et seq.).
26. Paller AS, Spergel JM, Mina-Osorio P, et al. The atopic march and atopic multimorbidity. J Allergy Clin Immunol. 2019;143(1):46-55.
27. Du Toit G, Roberts G, Sayre PH, et al. Randomized trial of peanut consumption in infants at risk for peanut allergy (LEAP). N Engl J Med. 2015;372(9):803-813.
28. Systemic therapy (pivotal trials)
29. Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo (SOLO 1 / SOLO 2). N Engl J Med. 2016;375(24):2335-2348.
30. Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130-139. PMID: 25006719.
31. Paller AS, Simpson EL, Siegfried EC, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis. Lancet. 2022;400(10356):908-919.
32. Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. Tralokinumab for moderate-to-severe atopic dermatitis (ECZTRA 1 and 2). Br J Dermatol. 2021;184(3):437-449.
33. Silverberg JI, Guttman-Yassky E, Thaçi D, et al. Lebrikizumab for moderate-to-severe atopic dermatitis (ADvocate 1 / 2). N Engl J Med. 2023;388(12):1080-1091.
34. Kabashima K, Matsumura T, Komazaki H, et al. Nemolizumab plus topical agents in patients with atopic dermatitis and pruritus (ARCADIA). Lancet. 2024;404(10468):1571-1582.
35. Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Upadacitinib in moderate-to-severe atopic dermatitis (Measure Up 1 / 2). Lancet. 2021;397(10290):2151-2168.
36. Bieber T, Simpson EL, Silverberg JI, et al. Abrocitinib versus placebo or dupilumab for atopic dermatitis (JADE COMPARE). N Engl J Med. 2021;384(12):1101-1112.
37. Simpson EL, Lacour JP, Spelman L, et al. Baricitinib in adults with moderate to severe atopic dermatitis (BREEZE-AD). Br J Dermatol. 2020;183(2):242-255.
38. Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis (ORAL Surveillance). N Engl J Med. 2022;386(4):316-326.
39. Hajar T, Leshem YA, Hanifin JM, et al. A systematic review of topical corticosteroid withdrawal ("steroid addiction"). J Am Acad Dermatol. 2015;72(3):541-549. PMID: 25592622.
40. Wollenberg A, Reitamo S, Atzori F, et al. Proactive treatment of atopic dermatitis with twice-weekly tacrolimus ointment. Allergy. 2008;63(7):742-750.